🇺🇸 FDA
Patent

US 10125171

Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof

granted A61KA61K38/00A61K47/60

Quick answer

US patent 10125171 (Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof) held by Apellis Pharmaceuticals, Inc. expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Apellis Pharmaceuticals, Inc.
Grant date
Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K38/00, A61K47/60, A61K47/643, A61P